Applications of Pitavastatin in Industrial Manufacturing

Pitavastatin serves as a specialized statin active pharmaceutical ingredient (API) primarily used in cardiovascular-focused pharmaceutical production. We supply pharmaceutical-grade Pitavastatin to qualified downstream manufacturers, supporting advanced formulations in line with strict international standards. Below are real-world industrial application scenarios covers the complete integration of our raw material into your downstream operations.

1. Cardiovascular Solid Oral Dosage Form Production

Leading pharmaceutical companies incorporate Pitavastatin as a key statin in the manufacturing of immediate-release tablets targeting hyperlipidemia and cardiovascular risk reduction. The API is blended with excipients in controlled environments, pressed into tablets, and film-coated to achieve required dissolution profiles. Manufacturers must ensure tight controls of active content and uniformity, with full traceability through batch records, given regulatory scrutiny on statin therapy products in global markets.

Industry compliance standards

• ICH Q7: Good Manufacturing Practice for Active Pharmaceutical Ingredients
• US FDA cGMP (21 CFR Parts 210/211)
• European Pharmacopoeia/Pitavastatin Monograph
• Japanese Pharmacopoeia

Typical usage ratio

• 0.5–4 mg per finished tablet, adjusted according to label strength (typically 1 mg, 2 mg, or 4 mg); API fraction 0.1–1% by tablet mass

Downstream process integration

• Direct addition of micronized API at the blending stage prior to granulation or direct compression; followed by tablet pressing and coating

Final product types

• Film-coated statin tablets (1 mg, 2 mg, 4 mg pack sizes)
• Blister-packed solid oral dosage forms
• Bulk tablets for contract packaging

2. Fixed-Dose Combination (FDC) Drug Manufacturing

Some manufacturers formulate fixed-dose combinations using Pitavastatin and other cardiovascular agents (such as antihypertensives or additional lipid-lowering compounds). This approach addresses multiple cardiovascular risk factors in a single tablet. Given the complexity of FDCs, the formulation must ensure both APIs remain chemically stable and bioavailable under finished product shelf-life and regulatory guidelines.

Industry compliance standards

• EMA Guideline on Clinical Development of Fixed Combination Medicinal Products
• US FDA Guidance on Co-Development of Two or More New Drugs
• Pharmacopoeial Monographs for Each API
• GMP Certification under PIC/S Scheme

Typical usage ratio

• Pitavastatin proportion per combination unit: 1–4 mg (the API ratio relative to co-formulated agents determined by clinical data and market requirement); 0.1–0.9% w/w in total tablet blend

Downstream process integration

• Sequential blending with secondary API powders, followed by wet granulation, drying, and tableting; additional QC for segregation and content uniformity

Final product types

• Bi-API and tri-API oral tablets for primary care markets
• Combinatorial pill pack lines
• Unit-dose combination therapy for cardiovascular disorders

3. Generic Statin Active Pharmaceutical Ingredient Preparation

Contract manufacturers use Pitavastatin as a starting material for generic statin drug formulation, aiming to comply with international bioequivalence requirements. The API undergoes micronization and is subjected to stringent identity, purity, and potency verification prior to downstream blending. Manufacturers often need to validate critical process parameters for regulatory dossiers, including dissolution profiles and impurity control.

Industry compliance standards

• WHO GMP (TRS 986, Annex 2)
• FDA ANDA Submission Standards (Bioequivalence, Dissolution)
• USP/NF Statin Monograph
• GMP Audit by Qualified Person (QP) for EU Exports

Typical usage ratio

• As supplied API for direct downstream formulation; final inclusion 0.05–1% w/w, modifiable per generic strength (1 mg, 2 mg, 4 mg units)

Downstream process integration

• API charging post-QC release; blending with direct compression or granulation excipients; inline monitoring of blend uniformity and content

Final product types

• Generic statin tablets
• Bulk-packaged active ingredient for compounding pharmacies
• Contract-manufactured private label tablets

4. Hospital Compounding and Pharmaceutical Bulk Processing

Large-scale hospital pharmacies and third-party bulk processors may acquire the pharmaceutical-grade raw material for reconstitution and extemporaneous preparation, particularly in scenarios where specific dosage forms are unavailable or individualized dosing is required. Materials are handled under secure protocols to ensure traceability and limit cross-contamination. Special requirements may apply for extemporaneous suspensions and oral liquids for certain patient demographics.

Industry compliance standards

• USP Chapter <795> Pharmaceutical Compounding—Nonsterile Preparations
• EU GMP Part I, Chapter 5: Production
• National Hospital Pharmacy Regulation (per region; e.g., US 503A/503B facilities)
• Local Pharmacopeia Standards

Typical usage ratio

• Preparation strengths adapted to prescription: typically 1–4 mg per unit dose; final formulation concentration range 0.1–1 mg/mL for liquid extemporaneous forms, calculated per patient prescription

Downstream process integration

• Weighing and dissolution of API for reconstitution into oral suspensions; batch compounding under controlled pharmacy conditions; immediate-use or short-term storage in compliance with USP

Final product types

• Oral suspension bottles (hospital in-house use)
• Individually compounded capsules or sachets
• Patient-specific extemporaneous dosage forms